

HiChem Industries (HiChem Paint Technologies)

Chemwatch: 58-0099 Version No: 2.1.1.1

Safety Data Sheet according to WHS and ADG requirements

Chemwatch Hazard Alert Code: 2

Issue Date: 15/09/2015 Print Date: 21/09/2015 Initial Date: Not Available L.GHS.AUS.EN

SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

Product Identifier

Product name	Polyurethane Sealant and Adhesive	
Synonyms	PUSEAL	
Other means of identification	Not Available	

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses A single pack, moisture cured polyure thane sealer and adhesive, applied by cartridge gun for filling and repair work on damaged automotive vehicles.

Details of the supplier of the safety data sheet

Registered company name	HiChem Industries (HiChem Paint Technologies)	
Address	'3 Hallam South Road Hallam 3803 VIC Australia	
Telephone	1 3 9796 3400	
Fax	61 3 9796 4500	
Website	www.hichem.com.au	
Email	info@hichem.com.au	

Emergency telephone number

Association / Organisation	Not Available	
Emergency telephone numbers	Not Available	
Other emergency telephone numbers	Not Available	

SECTION 2 HAZARDS IDENTIFICATION

Classification of the substance or mixture

HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. According to the Model WHS Regulations and the ADG Code.

CHEMWATCH HAZARD RATINGS

	Min	Max	
Flammability	1 📕	1	
Toxicity	1 📃		inimum
Body Contact	1 📃	1 = Lc	ow oderate
Reactivity	0	2 = W	
Chronic	2	4 = E>	dreme

Poisons Schedule	S5	
GHS Classification [1]	Flammable Liquid Category 4, Respiratory Sensitizer Category 1, Chronic Aquatic Hazard Category 4	
Legend:	1. Classified by Chernwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex VI	

Label elements

GHS label elements	
SIGNAL WORD	DANGER

Hazard statement(s)

H227	Combustible liquid	
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled	
H413	May cause long lasting harmful effects to aquatic life	

Precautionary statement(s) Prevention

· · · ·		
P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.	
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.	
P285	In case of inadequate ventilation wear respiratory protection.	
P273	Avoid release to the environment.	
P280	Wear protective gloves/protective clothing/eye protection/face protection.	

Precautionary statement(s) Response

P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.	
P342+P311	P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor/physician/first aider	
P370+P378 In case of fire: Use alcohol resistant foam or normal protein foam for extinction.		

Precautionary statement(s) Storage

P403+P235	Store in a well-ventilated place. Keep cool.
-----------	--

Precautionary statement(s) Disposal

P501

Dispose of contents/container in accordance with local regulations.

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
101-68-8	<0.5	4,4'-diphenylmethane diisocyanate (MDI)
Not Available	>60	Ingredients determined not to be hazardous

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret.

SECTION 4 FIRST AID MEASURES

Description of first aid measures

Eye Contact	 If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. 	
Skin Contact	 If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation. 	
Inhalation	 If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor. Following uptake by inhalation, move person to an area free from risk of further exposure. Oxygen or artificial respiration should be administered as needed. Asthmatic-type symptoms may develop and may be immediate or delayed up to several hours. Treatment is essentially symptomatic. A physician should be consulted. 	
Ingestion	Ingestion Immediately give a glass of water. First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.	

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 FIREFIGHTING MEASURES

Extinguishing media

- Foam.
- Dry chemical powder.

Special hazards arising fro	 BCF (where regulations permit). Carbon dioxide. Water spray or fog - Large fires only. om the substrate or mixture
Fire Incompatibility	None known.

Advice for firefighters

Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water courses. Use water delivered as a fine spray to control fire and cool adjacent area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	 Combustible. Slight fire hazard when exposed to heat or flame. Heating may cause expansion or decomposition leading to violent rupture of containers. On combustion, may emit toxic fumes of carbon monoxide (CO). May emit acrid smoke. Mists containing combustible materials may be explosive. May emit poisonous fumes.May emit corrosive fumes.

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Minor Spills	 Clean up all spills immediately. Avoid contact with skin and eyes. Wear impervious gloves and safety goggles. Trowel up/scrape up. Place spilled material in clean, dry, sealed container. Flush spill area with water.
Major Spills	 Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water course. Stop leak if safe to do so. Contain spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Neutralise/decontaminate residue (see Section 13 for specific agent). Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains. After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. If contamination of drains or waterways occurs, advise emergency services.
	Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling

	Avoid all personal contact, including inhalation.
	 Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area.
	 Prevent concentration in hollows and sumps.
	 DO NOT enter confined spaces until atmosphere has been checked.
	 DO NOT allow material to contact humans, exposed food or food utensits.
	 Avoid contact with incompatible materials.
Safe handling	When handling, DO NOT eat, drink or smoke.
Ū	Keep containers securely sealed when not in use.
	 Avoid physical damage to containers.
	Always wash hands with soap and water after handling.
	 Work clothes should be laundered separately. Launder contaminated clothing before re-use.
	 Use good occupational work practice.
	 Observe manufacturer's storage and handling recommendations contained within this MSDS.
	Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
	► Store in original containers.
	 Keep containers securely sealed.
Other information	Store in a cool, dry, well-ventilated area.
	 Store away from incompatible materials and foodstuff containers.
	Protect containers against physical damage and check regularly for leaks.
	Observe manufacturer's storage and handling recommendations contained within this MSDS.

Conditions for safe storage, including any incompatibilities

Suitable container	 Metal can or drum Packaging as recommended by manufacturer. Check all containers are clearly labelled and free from leaks. 	
Storage incompatibility	None known	

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA									
Source	Ingredient	Material name		TWA		STEL		Peak	Notes
Australia Exposure Standards	4,4'-diphenylmethane diisocyanate (MDI)	Methylene bisphenyl isocyanate	(MDI) Not Available N		Not Available		Not Availabl	e Not Available	
EMERGENCY LIMITS									
Ingredient	Material name				TEEL-1		TEEL	2	TEEL-3
4,4'-diphenylmethane diisocyanate (MDI)	Methylene diphenyl diisocyanate; (Diphenylmethane diisocyanate; MDI)				0.45 mg/m3		Not Available		Not Available
4,4'-diphenylmethane diisocyanate (MDI)	Methylenebis(isocyanato-benzene), 1,1'-; (Diphenyl methane diisocyanate)				40 mg/m	13	40 mg	g/m3	240 mg/m3
Ingredient	Original IDLH R		Revise	d IDLH					
4,4'-diphenylmethane diisocyanate (MDI)	100 mg/m3		75 mg/n	n3					
Ingredients determined not to be hazardous	Not Available			ailable					

MATERIAL DATA

Exposure controls

	Engineering controls are used to remove a hazard or place a barrier between the worker and the ha effective in protecting workers and will typically be independent of worker interactions to provide this The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the risk. Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designe the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure. Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Of Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ens An approved self contained breathing apparatus (SCBA) may be required in some situations. Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in th turn, determine the "capture velocities" of fresh circulating air required to effectively remove the cont	high level of protection. the worker and ventilation that stra d properly. The design of a ventilation correct fit is essential to obtain adec ure adequate protection. e workplace possess varying "esca	tegically "adds" and on system must match quate protection. upe" velocities which, in
	Type of Contaminant:		Air Speed:
	solvent, vapours, degreasing etc., evaporating from tank (in still air).		
Appropriate engineering	aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)		
controls	direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)		
	grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).		
	Within each range the appropriate value depends on:		
	Lower end of the range	Upper end of the range	
	1: Room air currents minimal or favourable to capture	1: Disturbing room air currents	
	2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity	
	3: Intermittent, low production.	3: High production, heavy use	
	4: Large hood or large air mass in motion	4: Small hood-local control only	
	Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple ex of distance from the extraction point (in simple cases). Therefore the air speed at the extraction poin distance from the contaminating source. The air velocity at the extraction fan, for example, should be solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerat apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more whe	t should be adjusted, accordingly, a a minimum of 1-2 m/s (200-400 f/n ions, producing performance deficit	after reference to hin) for extraction of ts within the extraction
Personal protection			

- Safety glasses with side shields.
- Chemical goggles.

Eye and face protection

Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH

	Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]
Skin protection	See Hand protection below
Hands/feet protection	 Wear chemical protective gloves, e.g. PVC. Wear safety footwear or safety gumboots, e.g. Rubber
Body protection	See Other protection below
Other protection	 Overalls. P.V.C. apron. Barrier cream. Skin cleansing cream. Eye wash unit.
Thermal hazards	Not Available

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the: "Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

Polyurethane Sealant and Adhesive

Material	CPI
PE/EVAL/PE	A

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as

"feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required.

Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS	-	A-PAPR-AUS / Class 1
up to 50 x ES	-	A-AUS / Class 1	-
up to 100 x ES	-	A-2	A-PAPR-2 ^

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Appearance	Coloured viscous paste with pungent odour; not miscible with water.		
Physical state	Free-flowing Paste	Relative density (Water = 1)	1.6
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	232
pH (as supplied)	Not Applicable	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	196	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	>61	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Combustible.	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Applicable
Vapour pressure (kPa)	Not Applicable	Gas group	Not Available
Solubility in water (g/L)	Immiscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	<1	VOC g/L	Not Available

SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	Product is considered stable and hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Information on toxicological effects

Inhaled	Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may be damaging to the health of the individual. Limited evidence or practical experience suggests that the material may produce irritation of the respiratory system, in a significant number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system.		
Ingestion	The material has NOT been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing morbidity rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.		
Skin Contact	Limited evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin pro to the use of the material and ensure that any external damage is suitably protected.		
Eye	Limited evidence exists, or practical experience suggests, that the material may cause eye irritation in a substantial number of individuals and/or is expected to produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.		
Chronic	Practical evidence shows that inhalation of the material is capable of inducing a sensitisation reaction in a substantial number of individuals at a greater frequency than would be expected from the response of a normal population. Pulmonary sensitisation, resulting in hyperactive airway dysfunction and pulmonary allergy may be accompanied by fatigue, malaise and aching. Significant symptoms of exposure may persist for extended periods, even after exposure ceases. Symptoms can be activated by a variety of nonspecific environmental stimuli such as automobile exhaust, perfumes and passive smoking.		
	ΤΟΧΙΟΙΤΥ	IRRITATION	
Polyurethane Sealant and Adhesive	Not Available	Not Available	
	ΤΟΧΙΟΙΤΥ	IRRITATION	
	Dermal (rabbit) LD50: >6200 mg/kg** ^[2]	[* = Bayer CCINFO 2133615]	
4,4'-diphenylmethane	Inhalation (rat) LC50: 0.49 mg/l4 h ^[1]	Dermal Sensitiser *	
diisocyanate (MDI)	Oral (rat) LD50: >2000 mg/kg ^[1]	Respiratory Sensitiser (g.pig) *	
		Skin (rabbit): 500 mg /24 hours	
Legend:	 Value obtained from Europe ECHA Registered Substances - Acu extracted from RTECS - Register of Toxic Effect of chemical Substances 	te toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data ances	
4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI)	 involves a cell-mediated (T lymphocytes) immune reaction of the omediated immune reactions. The significance of the contact allerg and the opportunities for contact with it are equally important. A withan one with stronger sensitising potential with which few individu produce an allergic test reaction in more than 1% of the persons the Asthma-like symptoms may continue for months or even years after as reactive airways dysfunction syndrome (RADS) which can occidiagnosis of RADS include the absence of preceding respiratory of within minutes to hours of a documented exposure to the irritant. A bronchial hyperreactivity on methacholine challenge testing and the in the criteria for diagnosis of RADS. RADS (or asthma) following of and duration of exposure to the irritating substance. Industrial b concentrations of irritating substance (often particulate in nature) dyspnea, cough and mucus production. Allergic reactions which develop in the respiratory passages as b with specific antibodies of the IgE class and belong in their reactic potential for causing respiratory sensitisation, the amount of the al person are likely to be decisive. Factors which increase the sensiti genetically determined or acquired, for example, during infections substances become complete allergens in the organism either by Particular attention is drawn to so-called atopic diathesis which is asstoma and atopic eczema (neurodermatitis) which is associated Exogenous allergic alveolitis is induced essentially by allergen spi be involved. Such allergy is of the delayed type with onset up to for 	, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody- gen is not simply determined by its sensitisation potential: the distribution of the substance eakly sensitising substance which is widely distributed can be a more important allergen ials come into contact. From a clinical point of view, substances are noteworthy if they ested.	

In general, there appears to the lifts or no difference between aromatic and alphabic discogrames are touched. In addition, there are insufficient data weeklike is animality by the rhotation coats, both aromatic and alphabic discogrames appear to be dript accoments in preduce data could be proved and alphabic discogrames are acuely took to the inhibition route. Note methods in animality the inhibition could, both aromatic and alphabic discogrames are acuely took to the inhibition route. Note methods in advantable to method and alphabic discogrames are acuely took to the inhibition route. Note methods are and alphabic discogrames are acuely took to the inhibition route. Note methods are and alphabic discogrames are acuely took to the inhibition route. The descrete of more human data, the second and alphabic discogrames are acuely took took and guine and second alphabic discogrames are acuely took took and guine and second alphabic discogrames are acuely took took and guine and second and alphabic discogrames are acuely took took and guine and guine discogrames are acuely took are the index of anomatic vesus affraids discogrames are acuely took are too and alphabic discogrames are acuely took are too and alphabic discogrames are acuely took are too and and alphabic discogrames are acuely took are acuerated and alphabic discogrames are acuely took are according and and alphabic discogrames are acuely took are according and and and and alphabic discogrames are acuely took are according and and and alphabic discogrames are acuely took are according and and and and alphabic discogrames are acuely took are according and and alphabic discogrames are acuely took are according and and and alphabic discogrames are acuely took are according and and and alphabic discogrames are acuely too	
 in a 2-year instation study in rats. The tested material contained 47% aromatic 4.4-methydenedipleryd discograntel (NDI) and 53% higher molecular weight oligomers. Interin sacifices at one year showed that males and females in the highest dose group (6 mg/mg/m) had treatment related histological changes in the nesal cavity, large and mediastinal lymph nodes. The incidence and severity of degeneration and basal cell hyperplasia of the olfactory explosing period. Pluronary adenomas were found in Famales and 2 females, and durinoary adenocans were found in Famales and 2 females. The incidence and severity of degeneration and basal cell hyperplasia of the olfactory exposure period. Pluronary adenomas were found in Famales and 2 females, and outprover and in the high dose group. However, alphatic hexamethylene discogranate (HDI) was found to be carcinogenic in a two year repeated dose studies by the oral route, aromatic fuluene discogranate (10) and 3.3^{outprovers}. The indicate of liver turnors in rats and mice as well as dose-related hemangiosarcomas of the circulatory system and has been disclifed by the Appeny as 8 B2 carcinogen. DADI was found to be carcinogenic in rotates. The indicates of pancreatic turnos charmed. Respiratory and Dermal Bensitization: Based on the available toxicity data in animals and epidemiologic studies of humans, aromatic discogranates such as TDI and MDI are strong respiratory sensitization. Huwever, HDI and possibly isophonen discogranate (PDI), are reported to be associated with respiratory sensitization in humans. Simptoms resulting from occupational exposure to HDI include shortses of breach, increases bronchoconstriction reaction bialingene, asthore of the informatic reactions, wheezing and coughing. Two case reports of humans aroma exposure to HDI include shortses of the methylene table on adjivation in humans. Simptoms resulting from occupational exposure to HDI include shortses of therease than the table in adjivation in humans. In view of the informat	available to make any major distinctions between polymeric (<1000 MW) and monomeric diisocyanates. Based on repeated dose studies in animals by the inhalation route, both aromatic and aliphatic diisocyanates appear to be of high concern for pulmonary toxicity at low exposure levels. Based upon a very limited data set, it appears that diisocyanates prepolymers exhibit the same respiratory tract effects as the monomers in repeated dose studies. There is also evidence that both aromatic and aliphatic diisocyanates are acutely toxic via the inhalation route. Most members of the diisocyanate category have not been tested for carcinogenic potential. Though the aromatic diisocyanates tested positive and the one aliphatic diisocyanate sted en species, it is premature to make any generalizations about the carcinogenic potential of aromatic versus aliphatic diisocyanates. In the absence of more human data, it would be prudent at this time to assume that both aromatic and aliphatic diisocyanates are respiratory sensitisers. Diisocyanates are moderate to strong dermal sensitisers in animal studies. Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanates. For monomers, effects on the respiratory tract (lungs and nasal cavities) were observed in animal studies at exposure concentrations of less than 0.005 mg/L. The experimental animal data available on prepolymeric diisocyanates show similar adverse effects at levels that range from 0.002 mg/L to 0.026 mg/L. There is also evidence that both aromatic and aliphatic diisocyanates are acutely toxic via the inhalation route
epithelium and Bowmar's gland hyperplasia were increased in males and 2 females, and pulmonary adenocarcinoma in one male in the high dose following the two year exposure period. Pulmonary adenomas were found in 6 males and 2 females, and pulmonary adenocarcinoma in one male in the high dose group. However, alphalic hexamethylene diisocyanate (HD) was found not to be carcinogenic in a two year repeated dose study in rats by the inhalation route. HDI has not been tested in mice by the inhalation route. HDI has not to been diisocyanate (HDI) and 3.3-dimethoxy-benzidine-4.4-disocyanate (dianisidine diisocyanate, DAD) were found to be carcinogenic in rotote, aromatic toluene diisocyanate (JDI) and 3.3-dimethoxy-benzidine-4.4-disocyanate (dianisidine diisocyanate, DAD) were found to be carcinogenic in rotote. TDI induced a statistically significant increase in the incidence of liver turnors in trast and mice as well as dose-related hermangioscaronas of the circulatory system and has been classified by the Agency as a B2 carcinogen. DADI was found to be carcinogenic in rats, but not in mice, with a statistically increase in the incidence of pancreaic turnos observed. Respiratory and Dermal Sensitization: Based on the available toxicity data in animals and epidemiologic studies of humans, aromatic diisocyanates such as TDI and MDI are strong respiratory sensitisers. Aliphatic diisocyanates are generally not active in animal models for respiratory sensitization. However, HDI and possibly isophoren observes for breath, increased bronchoconstriction reaction to histamine challenges, sathmatic reactions, wheering and coughing. Two case reports of human exposure to IPDI by inhalation sugget IPDI is a respiratory sensities in humans, it would be prudent at this the tasis on an aliphatic diisocyanate (HDI) sugget cross-reactivity with the other diisocyanate (HDI) moles and gluice pigs. Bormal Intration: Studies in the skin in gluine pigs. Bormal Intration: Studies performed on rabitis and gluine pigs.	in a 2-year inhalation study in rats. The tested material contained 47% aromatic 4,4'-methylenediphenyl diisocyanate (MDI) and 53% higher molecular weight oligomers. Interim sacrifices at one year showed that males and females in the highest dose group (6 mg/m3) had treatment related histological
 Though the oral route is not an expected route of exposure to humans, it should be noted that in two year repeated does studies by the oral route, aromatic toluene discoyanate (TDI) and 3,3-dimethoxy-berzidine-4,4-discoyanate (dianisidine discoyanate, DADI) were found to be carcinogenic in the circulatory system and has been classified by the Agency as a B2 carcinogen. DADI was found to be carcinogenic in rais, but not in mice, with a statistically increase in the incidence of lawer tumors in raist and mice as well as does-related hemapilicaaromas of the circulatory system and has been classified by the Agency as a B2 carcinogen. DADI was found to be carcinogenic in rais, but not in mice, with a statistically increase in the incidence of pancreatic tumors observed. Respiratory and Dermal Sensitization: Based on the available toxicity data in animals and epidemiologic studies of humans, aromatic diisocyanates such as TDI and MDI are strong respiratory sensitiaers in humans. Thymotom sesulting from occupational exposure to HDI include shortness of breakt, increased bronchocconstriction reaction to histamine challenges, asthmatic reactions, wheezing and coughing. Two case reports of human exposure to IPDI by inhalation suggest IPDI is a respiratory sensitizer in humans. It would be prudent at this time to assume that both aromatic and alphatic discoyanates are moderate to strong dermal sensitisers. Studies in both human and mice using TDI, HDI, MDI and dicyclohexylmethane-4,4-discoyanate. Sincoyanate and the other discoyanates. The level of irritation sudges performed on rabits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic discoyanates. Dormal Irritation: Skin intration studies performed on rabits and guinea pigs. Isocyanate as an ellophatic on effort or anomatic discoyanates. Sincoyanate exposure include headache, insormaia, euphonia, ataxia, anxidy neurois, depression and paranoia. Castrointestinal disturbances are characterised by nauses and vom	epithelium and Bowman's gland hyperplasia were increased in males at the mid and high doses and in females at the high dose following the two year exposure period. Pulmonary adenomas were found in 6 males and 2 females, and pulmonary adenocarcinoma in one male in the high dose group. However, aliphatic hexamethylene disocyanate (HDI) was found not to be carcinogenic in a two year repeated dose study in rats by the inhalation route. HDI has not
 such as TD and MDI are strong respiratory sensitisers. Aliphatic diisocyanates are generally not active in animal models for respiratory sensitization. However, HDI and possibly isophorone diisocyanate (IPDI), are reported to be associated with respiratory sensitization in humans. Symptoms resulting from occupational exposure to HDI include shortness of breath, increased bronchoconstriction reaction to histamine challenges, asthmatic reactions, wheezing and coughing. Two case reports of human exposure to IPDI by inhalation suggest IPDI is a respiratory sensitizer in humans. In view of the information from case reports in humans, it would be prudent at this time to assume that both aromatic and aliphatic diisocyanates are respiratory sensitisers. Studies in both human and mice using TDI, HDI, MDI and dicyclohexylmethane-4,4'-disocyanate (HMDI) suggest cross-reactivity with the other diisocyanates, inrespective of whether the challenge compound was an aliphatic or aromatic diisocyanate are moderate to storng demal sensitisers in animal studies. There seems to be little or no difference in the level of reactivity between aromatic and aliphatic diisocyanates. Dermal Irritation: Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanate server exposure/sixe to the skin in guinea pigs. Isocyanate vapours/mists are irritating to the upper respiratory tract and lungs; the response may be severe enough to produce bronchitis with wheezing, gasping and severe distress, even sudden loss of consciousness, and pulmonary oedema. Possible neurological symptoms arising from isocyanate exposure following a single acute exposure or may develop without warning after a period of tolerance. A respiratory response may occur following minor skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities. Isocyanate containing wapous/ mist may	Though the oral route is not an expected route of exposure to humans, it should be noted that in two year repeated dose studies by the oral route, aromatic toluene diisocyanate (TDI) and 3,3'-dimethoxy-benzidine-4,4'-diisocyanate (dianisidine diisocyanate, DADI) were found to be carcinogenic in rodents. TDI induced a statistically significant increase in the incidence of liver tumors in rats and mice as well as dose-related hemangiosarcomas of the circulatory system and has been classified by the Agency as a B2 carcinogen. DADI was found to be carcinogenic in rats, but not in mice, with a statistically increase
 sensitisers. Studies in both human and mice using TDI, HDI, MDI and dicyclohexylmethane-4,4'-diisocyanate (HMDI) suggest cross-reactivity with the other diisocyanates, irrespective of whether the challenge compound was an aliphatic or aromatic diisocyanate. Diisocyanates are moderate to strong dermal sensitisers in animal studies. There seems to be little or no difference in the level of reactivity between aromatic and aliphatic diisocyanates. Dermal Irritation: Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanates. The level of irritation ranged from slightly to severely irritating to the skin. One chemical, hydrogenated MDI (1,1-methylenebis-4-isocyanatocyclohexane), was found to be corrosive to the skin in guinea pigs. Isocyanate vapours/mists are irritating to the upper respiratory tract and lungs; the response may be severe enough to produce bronchitis with wheezing, gasping and severe distress, even sudden loss of consciousness, and pulmonary oedema. Possible neurological symptoms arising from isocyanate exposure include headache, insomnia, euphoria, ataxia, anxiety neurosis, depression and paranoia. Gastrointestinal disturbances are characterised by nausea and vomiting. Pulmonary sensitisation may produce asthmatic reactions ranging from minor breathing difficulties to severe allergic attacks; this may occur following a single acute exposure or may develop without warning after a period of tolerance. A respiratory response may occur following minor skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities. Isocyanate-containing vapours/ mists may cause inflammation of eyes and nasal passage. Onset of symptoms may be immediate or delayed for several hours after exposure to this material. The substance is classified by IARC as Group 3: NOT classifiable as to its cariongenicity to hum	such as TDI and MDI are strong respiratory sensitisers. Aliphatic diisocyanates are generally not active in animal models for respiratory sensitization. However, HDI and possibly isophorone diisocyanate (IPDI), are reported to be associated with respiratory sensitization in humans. Symptoms resulting from occupational exposure to HDI include shortness of breath, increased bronchoconstriction reaction to histamine challenges, asthmatic reactions, wheezing and coughing. Two case reports of human exposure to IPDI by inhalation suggest IPDI is a respiratory sensitiser in humans. In view of the
Isocyanate vapours/mists are irritating to the upper respiratory tract and lungs; the response may be severe enough to produce bronchitis with wheezing, gasping and severe distress, even sudden loss of consciousness, and pulmonary oedema. Possible neurological symptoms arising from isocyanate exposure include headache, insomnia, euphoria, ataxia, anxiety neurosis, depression and paranoia. Gastrointestinal disturbances are characterised by nausea and vomiting. Pulmonary sensitisation may produce asthmatic reactions ranging from minor breathing difficulties to severe allergic attacks; this may occur following a single acute exposure or may develop without warning after a period of tolerance. A respiratory response may occur following minor skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities. Isocyanate-containing vapours/ mists may cause inflammation of eyes and nasal passages. Onset of symptoms may be immediate or delayed for several hours after exposure. Sensitised people can react to very low levels of airborne isocyanates. Unprotected or sensitised persons should not be allowed to work in situations allowing exposure to this material. The substance is classified by IARC as Group 3: NOT classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.	sensitisers. Studies in both human and mice using TDI, HDI, MDI and dicyclohexylmethane-4,4-diisocyanate (HMDI) suggest cross-reactivity with the other diisocyanates, irrespective of whether the challenge compound was an aliphatic or aromatic diisocyanate. Diisocyanates are moderate to strong dermal sensitisers in animal studies. There seems to be little or no difference in the level of reactivity between aromatic and aliphatic diisocyanates. Dermal Irritation: Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanates. The level of irritation ranged from slightly to severely irritating to the skin. One chemical, hydrogenated MDI (1,1-methylenebis-
skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities. Isocyanate-containing vapours/ mists may cause inflammation of eyes and nasal passages. Onset of symptoms may be immediate or delayed for several hours after exposure. Sensitised people can react to very low levels of airborne isocyanates. Unprotected or sensitised persons should not be allowed to work in situations allowing exposure to this material. The substance is classified by IARC as Group 3: NOT classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.	Isocyanate vapours/mists are irritating to the upper respiratory tract and lungs; the response may be severe enough to produce bronchitis with wheezing, gasping and severe distress, even sudden loss of consciousness, and pulmonary oedema. Possible neurological symptoms arising from isocyanate exposure include headache, insomnia, euphoria, ataxia, anxiety neurosis, depression and paranoia. Gastrointestinal disturbances are characterised by nausea and vomiting. Pulmonary sensitisation may produce asthmatic reactions ranging from minor breathing difficulties to severe allergic attacks; this
NOT classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.	skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities. Isocyanate-containing vapours/ mists may cause inflammation of eyes and nasal passages. Onset of symptoms may be immediate or delayed for several hours after exposure. Sensitised people can react to very low levels of airborne isocyanates. Unprotected or sensitised persons should not be allowed to work in situations allowing exposure to this material.
	NOT classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.

Acute Toxicity	\otimes	Carcinogenicity	\otimes
Skin Irritation/Corrosion	0	Reproductivity	0
Serious Eye Damage/Irritation	\otimes	STOT - Single Exposure	\otimes
Respiratory or Skin sensitisation	*	STOT - Repeated Exposure	0
Mutagenicity	0	Aspiration Hazard	\otimes

Legend:

Data required to make classification available

 $\dot{\mathbf{X}}$ – Data available but does not fill the criteria for classification \odot – Data Not Available to make classification

SECTION 12 ECOLOGICAL INFORMATION

Toxicity

NOT AVAILABLE

Ingredient	Endpoint	Test Duration	Effect	Value	Species	BCF
4,4'-diphenylmethane diisocyanate (MDI)	Not Available					
Ingredients determined not to be hazardous	Not Available					

May cause long-term adverse effects in the aquatic environment.

Do NOT allow product to come in contact with surface waters or to intertidal areas below the mean high water mark. Do not contaminate water when cleaning equipment or disposing of equipment wash-waters.

Wastes resulting from use of the product must be disposed of on site or at approved waste sites. **DO NOT** discharge into sewer or waterways.

Persistence and degradability

- - - -		
Ingredient	Persistence: Water/Soil	Persistence: Air
4,4'-diphenylmethane diisocyanate (MDI)	LOW (Half-life = 1 days)	LOW (Half-life = 0.24 days)
Bioaccumulative potentia	I. Contraction of the second se	
Ingredient	Bioaccumulation	
4,4'-diphenylmethane diisocyanate (MDI)	LOW (BCF = 15)	
Mobility in soil		
Ingredient	Mobility	
4,4'-diphenylmethane diisocyanate (MDI)	LOW (KOC = 376200)	

SECTION 13 DISPOSAL CONSIDERATIONS

Waste treatment methods

 Bury residue in an authorised landfill. Recycle containers if possible, or dispose of in an authorised landfill. 	Product / Packaging disposal	 Containers may still present a chemical hazard/ danger when empty. Return to supplier for reuse/ recycling if possible. Otherwise: If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill. Where possible retain label warnings and MSDS and observe all notices pertaining to the product. Recycle wherever possible or consult manufacturer for recycling options. Consult State Land Waste Management Authority for disposal. Bury residue in an authorised landfill. Recycle containers if possible, or dispose of in an authorised landfill.
---	---------------------------------	---

SECTION 14 TRANSPORT INFORMATION

Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL 73 / 78 and the IBC code

Source	Ingredient	Pollution Category
IMO MARPOL 73/78 (Annex II) - List of Noxious Liquid Substances Carried in Bulk	4,4'-diphenylmethane diisocyanate (MDI)	Y

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI)(101-68-8) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Exposure Standards	Australia Inventory of Chemical Substances (AICS)
Australia Hazardous Substances Information System - Consolidated Lists	International Agency for Research on Cancer (IARC) - Agents Classified by the IARC
	Monographs

National Inventory	Status
Australia - AICS	Υ
Canada - DSL	Y
Canada - NDSL	N (4,4'-diphenylmethane diisocyanate (MDI))
China - IECSC	Y
Europe - EINEC / ELINCS / NLP	Y
Japan - ENCS	Y
Korea - KECI	Y
New Zealand - NZIoC	Y
Philippines - PICCS	Y
USA - TSCA	Y
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16 OTHER INFORMATION

Other information

Ingredients with multiple cas numbers

4,4'-diphenylmethane diisocyanate (MDI) 101-68-8, 26447-40-5	

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

A list of reference resources used to assist the committee may be found at:

www.chemwatch.net

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.

